CA2346684A1 - Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek - Google Patents
Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek Download PDFInfo
- Publication number
- CA2346684A1 CA2346684A1 CA002346684A CA2346684A CA2346684A1 CA 2346684 A1 CA2346684 A1 CA 2346684A1 CA 002346684 A CA002346684 A CA 002346684A CA 2346684 A CA2346684 A CA 2346684A CA 2346684 A1 CA2346684 A1 CA 2346684A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- phenylamino
- iodo
- benzamide
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La présente invention concerne un procédé concernant la prophylaxie ou la maintenance du rejet des transplants d'organes, de cellules, de membres et de tissus chez les mammifères. Ce procédé consiste en une administration d'un inhibiteur sélectif du MEK, de préférence un composé représenté par les formules I et II.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11236998P | 1998-12-15 | 1998-12-15 | |
US60/112,369 | 1998-12-15 | ||
PCT/US1999/029591 WO2000035435A1 (fr) | 1998-12-15 | 1999-12-14 | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2346684A1 true CA2346684A1 (fr) | 2000-06-22 |
Family
ID=22343544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002346684A Abandoned CA2346684A1 (fr) | 1998-12-15 | 1999-12-14 | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1140046A1 (fr) |
JP (1) | JP2002532414A (fr) |
KR (1) | KR20010101203A (fr) |
AU (1) | AU2180500A (fr) |
CA (1) | CA2346684A1 (fr) |
HU (1) | HUP0104607A3 (fr) |
IL (1) | IL143231A0 (fr) |
TR (1) | TR200101704T2 (fr) |
WO (1) | WO2000035435A1 (fr) |
ZA (1) | ZA200103765B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
ME01480B (fr) | 2004-06-11 | 2014-04-20 | Japan Tobacco Inc | Dérivés de 5-amino-2,4,7-trioxo-3,4,7,8-tétrahydro-2h-pyrido'2,3-d! pyrimidine et composés apparentés pour le traitement du cancer |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
WO2007054556A1 (fr) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Nouvelle pyridopyrazine et son utilisation pour la modulation de kinases |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (fr) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal |
JP2009537542A (ja) | 2006-05-19 | 2009-10-29 | ワイス | ヒスタミン−3アンタゴニストとしてのn−ベンゾイルピロリジン−3−イルアミンおよびn−ベンジルピロリジン−3−イルアミン |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
JP5746630B2 (ja) | 2008-11-10 | 2015-07-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換スルホンアミドフェノキシベンズアミド |
WO2011047795A1 (fr) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Benzosulfonamides substitués |
CA2777304A1 (fr) | 2009-10-21 | 2011-04-28 | Marion Hitchcock | Benzosulfonamides substitues |
EP2491014A1 (fr) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Dérivés d'halogénophénoxybenzamide substitués |
US9045429B2 (en) | 2010-10-29 | 2015-06-02 | Bayer Intellectual Property Gmbh | Substituted phenoxypyridines |
SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
WO2020142745A1 (fr) * | 2019-01-04 | 2020-07-09 | Translational Drug Development, Llc | Procédés de traitement d'une maladie du greffon contre l'hôte et d'une maladie néoplasique avec des composés amide |
JP2021522238A (ja) | 2018-04-24 | 2021-08-30 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155110A (en) * | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
AU5259296A (en) * | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
WO1998037881A1 (fr) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek |
PT993439E (pt) * | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
NZ501277A (en) * | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
WO1999034792A1 (fr) * | 1998-01-06 | 1999-07-15 | The General Hospital Corporation | Utilisation des inhibiteurs de mek1 comme agents protecteurs contre les lesions consecutives a l'ischemie |
-
1999
- 1999-12-14 HU HU0104607A patent/HUP0104607A3/hu unknown
- 1999-12-14 TR TR2001/01704T patent/TR200101704T2/xx unknown
- 1999-12-14 CA CA002346684A patent/CA2346684A1/fr not_active Abandoned
- 1999-12-14 AU AU21805/00A patent/AU2180500A/en not_active Abandoned
- 1999-12-14 IL IL14323199A patent/IL143231A0/xx unknown
- 1999-12-14 EP EP99966203A patent/EP1140046A1/fr not_active Withdrawn
- 1999-12-14 WO PCT/US1999/029591 patent/WO2000035435A1/fr not_active Application Discontinuation
- 1999-12-14 JP JP2000587756A patent/JP2002532414A/ja active Pending
- 1999-12-14 KR KR1020017007397A patent/KR20010101203A/ko not_active Application Discontinuation
-
2001
- 2001-05-09 ZA ZA200103765A patent/ZA200103765B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200103765B (en) | 2002-05-09 |
TR200101704T2 (tr) | 2001-11-21 |
WO2000035435A9 (fr) | 2001-03-22 |
KR20010101203A (ko) | 2001-11-14 |
HUP0104607A3 (en) | 2002-12-28 |
IL143231A0 (en) | 2002-04-21 |
JP2002532414A (ja) | 2002-10-02 |
WO2000035435A1 (fr) | 2000-06-22 |
EP1140046A1 (fr) | 2001-10-10 |
AU2180500A (en) | 2000-07-03 |
HUP0104607A2 (hu) | 2002-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU776788B2 (en) | Treatment of arthritis with MEK inhibitors | |
US6251943B1 (en) | Method of treating or preventing septic shock by administering a MEK inhibitor | |
CA2346684A1 (fr) | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek | |
EP1140062B1 (fr) | Traitement de l'asthme a l'aide d'inhibiteurs de mek | |
EP1140291B1 (fr) | Chimiotherapie utilisant un inhibiteur de la mitose avec un inhibiteur mek | |
ZA200104000B (en) | Antiviral method using MEK inhibitors. | |
US20030055095A1 (en) | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | |
US20040171632A1 (en) | Combination chemotherapy | |
ZA200104277B (en) | Combination chemotherapy. | |
MXPA01005476A (en) | Combination chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |